Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31651330 | 0.86 | ADORA2A (0.33) | ADORA2AADORA1AADATBRAF | |
| SCHEMBL21962406 | 0.84 | CA12 (0.31) | CA12CA1CA2CA9CA7 | |
| SCHEMBL22021180 | 0.80 | ADORA2A (0.36) | ADORA2AADORA1CA12CA1CA2 | |
| SCHEMBL22021472 | 0.79 | ADORA2A (0.41) | ADORA2AADORA1CA12CA1CA2 | |
| SCHEMBL22019999 | 0.77 | APLNR (0.32) | — | |
| SCHEMBL29056893 | 0.75 | PTGS2 (0.33) | ADORA2AADORA1 | |
| SCHEMBL21963233 | 0.75 | CA1 (0.35) | ADORA2AADORA1CA12CA1CA2 | |
| SCHEMBL21962705 | 0.72 | NLRP3 (0.44) | — | |
| SCHEMBL25085525 | 0.72 | NLRP3 (0.44) | — | |
| SCHEMBL21962703 | 0.72 | NLRP3 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106289-A1 | NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-04-07 | — | — | US | disclosed |
| US-20220106289-A1 | NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-04-07 | — | — | US | disclosed |
| EP-3883646-A1 | NLRP3 INHIBITORS | Inflazome Limited (IE) | 2021-09-29 | — | — | EP | disclosed |
| CN-113164763-A | NLRP3 inhibitor | 英夫拉索姆有限公司 | 2021-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106289-A1 | NLRP3 INHIBITORS | NLRP3, NLRP1, NOD1 | ADORA2A 1355/4885ADORA1 1741/4885CA12 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.